Inhalation Sciences’ in-vitro technology XposeALI® granted patent in China

Inhalation Sciences’ patent application for XposeALI®, the company's unique, proprietary module for aerosol exposure of cells, has been approved in China. The product patent, which includes the design of the product, applies until the end of 2033. Inhalation Sciences’ products are protected by a total of 6 patent families.

Inhalation Sciences (ISAB) develops advanced labtech R&D instruments used to study the effects of inhaled particles on the lungs and wider health. At the centre of the company’s technology is the PreciseInhale® system. A range of modules can be attached to PreciseInhale, depending on users’ research and development goals.

XposeALI® is the company’s proprietary module for the aerosol exposure of cells. The current module is in the early stages of commercialization and is installed at Karolinska Institute in Stockholm.

Fredrik Sjövall, CEO: “The approval of our patent in China is further proof of how innovative our products are. It is a strong basis for future expansion in China.”

For more information about Inhalation Sciences please contact:

Fredrik Sjövall, CEO 
Email: fredrik.sjovall@inhalation.se
Phone: +46 (0)70 64 508 75

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on September 27, 2017.